Faiena, Izak http://orcid.org/0000-0001-6095-2757
Astrow, Stephanie H.
Elashoff, David A.
Jain, Rajul
Bot, Adrian
Chamie, Karim
Belldegrun, Arie S.
Pantuck, Allan J.
Drakaki, Alexandra
Funding for this research was provided by:
Kite Pharma Inc. (SRA-2018-0493)
Article History
Received: 22 May 2018
Accepted: 15 February 2019
First Online: 21 February 2019
Compliance with ethical standards
:
: Izak Faiena and Alexandra Drakaki received research funding from Kite, a Gilead Company. Stephanie H. Astrow, Rajul Jain, and Adrian Bot are employees of Kite, a Gilead Company, and have equity ownership in Gilead Sciences, Inc. Arie S. Belldegrun is the founder and was formerly Chief Executive Officer of Kite, a Gilead Company, and has equity ownership in Gilead Sciences, Inc. Allan J. Pantuck has equity ownership in Gilead Sciences, Inc. The authors declare they have no other conflicts of interest.
: This study included de-identified data in a tissue microarray and was deemed to be an exempt study by the institutional review board (IRB #99–233) of the University of California, Los Angeles for TMA construction and data analysis; therefore, special ethical permission was not required. Requirement for consent was waived given the retrospective, de-identified nature of the samples, and the impracticality of consenting for samples stored prior to 1998.